Merck KGaA to buy Springworks for $3.9 billion Merck KGaA (OTCPK:MKGAF) is set to acquire SpringWorks Therapeutics (SWTX) for ...

A wave of new drugs have revolutionised the weight loss industry. Now, getting your hands on one popular medication could get ...

This report covers recent developments in the health sector, including proposed US federal budget cuts affecting scientific ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity, but is coming under competitive pressure ...

Novo Nordisk's GLP-1 receptor agonist semaglutide ... which is already seeing sales rocket on the back of its use as Ozempic for diabetes, Wegovy for obesity, and label extensions for both brands ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...